Contact
Please use this form to send email to PR contact of this press release:
Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Prostatic Neoplasms, Date of authorisation: 24/05/2022, Revision: 1, Status: Authorised
TO: